CN109401994A - 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 - Google Patents
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 Download PDFInfo
- Publication number
- CN109401994A CN109401994A CN201810978431.3A CN201810978431A CN109401994A CN 109401994 A CN109401994 A CN 109401994A CN 201810978431 A CN201810978431 A CN 201810978431A CN 109401994 A CN109401994 A CN 109401994A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- application
- effects
- hyperlipemia
- inhibit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 38
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 230000006378 damage Effects 0.000 claims abstract description 7
- 244000005700 microbiome Species 0.000 claims abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 5
- 208000014674 injury Diseases 0.000 claims abstract description 5
- 210000000496 pancreas Anatomy 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims description 13
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000006041 probiotic Substances 0.000 claims description 6
- 235000018291 probiotics Nutrition 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 235000009200 high fat diet Nutrition 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 230000036542 oxidative stress Effects 0.000 claims description 3
- 235000020167 acidified milk Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 235000021110 pickles Nutrition 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000011552 rat model Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000005418 vegetable material Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 5
- 240000007817 Olea europaea Species 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 206010020880 Hypertrophy Diseases 0.000 abstract description 3
- 210000001789 adipocyte Anatomy 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 238000003304 gavage Methods 0.000 abstract description 3
- 230000004792 oxidative damage Effects 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，菌株为鼠李糖乳杆菌NCU2217，已于2018年4月9日保藏在中国微生物菌种保藏管理委员会普通微生物中心，地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，其简称为CGMCC，保藏编号为CGMCC NO15573，鼠李糖乳杆菌CGMCC NO15573具有潜在的抵抗氧化损伤的能力，此鼠李糖乳杆菌CGMCC NO15573连续灌胃5周后胰腺损伤有所降低，脂肪细胞肥大症状有所缓解，所以该菌具有抑制脂肪肝和肥胖的功能。
Description
技术领域
本发明属微生物领域，具体是涉及一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用。
背景技术
鼠李糖乳杆菌是近年来国外研究较多的一种益生乳酸细菌，其广泛存在于传统的发酵乳制品和人体胃肠道中。已有大量资料表明，鼠李糖乳杆菌在益生菌领域有很广阔的开发及应用前景。目前研究结果已经证实鼠李糖乳杆菌具有以下益生功能：(1)抗菌作用。报道称，鼠李糖乳杆菌对食物及肠道中的一些致病菌具有抑制作用，其发酵所产生的抑菌物质对革兰氏阳性、阴性菌及多种致病菌均有抑制作用；(2)抗氧化作用。研究表明，鼠李糖乳杆菌的菌悬液、无细胞提取液及胞外多糖均具有较强的抗氧化活性；(3)免疫调节作用。鼠李糖乳杆菌能够增强小鼠肠道及系统的免疫应答，并且对小鼠细胞的迟发型变态反应、脾淋巴细胞增值能力以及NK细胞活性也具有显著效果；(4)治疗肠道疾病。但目前鼠李糖乳杆菌在抑制高血脂症方面的功效尚没有报道。
发明内容
本发明的目的是提供一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用。为实现以上目的，本发明提供了以下技术方案：
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，菌株为Lactobacillusrhamnosus鼠李糖乳杆菌NCU2217，已于2018年4月9日保藏在中国微生物菌种保藏管理委员会普通微生物中心，地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，其简称为CGMCC，保藏编号为CGMCC NO15573。
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用：所述的鼠李糖乳杆菌NCU2217为活菌或灭活菌或该菌株的衍生物。
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用：所述应用为应用于食品领域，所述的食品可以是发酵果蔬、发酵乳、乳酪、含乳饮料、乳粉或其他含有该菌株或该菌株衍生物的食品中的任何一种。
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用：所述具有缓解结肠炎功效具体表现为：对高脂饮食诱导高脂血症大鼠模型具有潜在的调节血脂功效、对高脂血症大鼠模型的氧化应激损伤有较好的缓解作用、能够改善高脂饮食大鼠胰腺和脂肪的微观结构，促进机体损伤修复。
一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用：所述应用为：鼠李糖乳杆菌以食品的形式组成组合物，发酵大宗果蔬产生酸鲜可口、营养丰富、天然果蔬味浓郁并具有良好保健功效的益生菌发酵果蔬产品，包括：泡菜、饮料、浆料，产品中无需添加任何香精香料、色素、酸味剂、稳定剂、防腐剂这些食品添加剂，所有风味由益生菌发酵果蔬原料产生。
本发明的有益效果：
鼠李糖乳杆菌CGMCC NO15573具有潜在的抵抗氧化损伤的能力，此鼠李糖乳杆菌CGMCC NO15573连续灌胃5周后胰腺损伤有所降低，脂肪细胞肥大症状有所缓解，该菌具有抑制脂肪肝和肥胖的功能。
附图说明
图1为口服葡萄糖后血糖浓度的变化。
图2为血清胰岛素、瘦素、脂联素水平。
图3为鼠李糖乳杆菌NCU2217对高脂饮食大鼠脂肪病理水平的影响。
具体实施方式
实验例
下面结合附图和实验例、测试数据，对本发明进行具体描述：
健康SD大鼠，雄性，120-150g，置于饲养环境下适应1周。随机将大鼠分为正常组(ND)、高脂模型组(HFD)、鼠李糖乳杆菌CGMCC NO15573低剂量组(108CFU/mL)和鼠李糖乳杆菌CGMCC NO15573高剂量组(109CFU/mL)4 组，每组10只。所有大鼠正常饮水，给予模型组、高剂量组和低剂量组高脂饲料。按照10mL/kg体重给高剂量组和低剂量组灌胃相应剂量的鼠李糖乳杆菌CGMCC NO15573，高脂模型组和正常组灌胃同等剂量生理盐水，连续5周。
实验过程中，定期称量体重，记录饮食、饮水情况，每周眼球取血，离心得血清。测定血清TC、TG、HDL-C和LDL-C水平，灌胃结束后，禁食过夜，心脏刺穿采血，离心得血清。放免法测定胰岛素(Insulin)、瘦素(Leptin)、脂联素(Adiponectin)含量。动物禁食不禁水12h，尾静脉取血(0min)测定血糖，给动物灌胃2g/kg BW剂量葡萄糖，分别在30min、60min、90min、 120min测定血糖值，然后采用试剂盒测定血清中SOD、GSH-Px、CAT等酶活力和MDA含量。实验结束后，大鼠经麻醉，分离胰腺、脂肪等组织称重并置于10％福尔马林固定液中固定，采用苏木素伊红(hematoxylin and eosin，H&E)染色进行病理学观察。
表1：实验过程中各组动物体重、摄食和饮水变化情况
表2：鼠李糖乳杆菌CGMCC NO15573对大鼠脂代谢水平的影响
表3：鼠李糖乳杆菌CGMCC NO15573对大鼠氧化应激水平的影响
实验结果如附表1、2、3及附图1、2、3，结果显示，鼠李糖乳杆菌CGMCC NO15573连续灌胃5周可以明显降低高脂饮食大鼠血清TC、TG和LDL-C并能提高HDL-C水平，摄入鼠李糖乳杆菌CGMCC NO15573能够显著提升SOD，GSH-Px 和CAT酶类活力，升高T-AOC水平，并降低MDA含量。因此，鼠李糖乳杆菌CGMCC NO15573具有潜在的抵抗氧化损伤的能力。此外，从病理学观察可知：鼠李糖乳杆菌CGMCC NO15573连续灌胃5周后胰腺损伤有所降低，脂肪细胞肥大症状有所缓解，提示该菌具有抑制脂肪肝和肥胖的功能。
Claims (5)
1.一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，菌株为鼠李糖乳杆菌NCU2217，已于2018年4月9日保藏在中国微生物菌种保藏管理委员会普通微生物中心，地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，其简称为CGMCC，保藏编号为CGMCC NO15573。
2.根据权利要求1所述的一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，其特征在于：所述的鼠李糖乳杆菌NCU2217为活菌或灭活菌或该菌株的衍生物。
3.根据权利要求1所述的一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，其特征在于：所述应用为应用于食品领域，所述的食品可以是发酵果蔬、发酵乳、乳酪、含乳饮料、乳粉或其他含有该菌株或该菌株衍生物的食品中的任何一种。
4.根据权利要求1所述的一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，其特征在于：所述具有缓解结肠炎功效具体表现为：对高脂饮食诱导高脂血症大鼠模型具有潜在的调节血脂功效、对高脂血症大鼠模型的氧化应激损伤有较好的缓解作用、能够改善高脂饮食大鼠胰腺和脂肪的微观结构，促进机体损伤修复。
5.根据权利要求1所述的一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用，其特征在于：所述应用为：鼠李糖乳杆菌以食品的形式组成组合物，发酵大宗果蔬产生酸鲜可口、营养丰富、天然果蔬味浓郁并具有良好保健功效的益生菌发酵果蔬产品，包括：泡菜、饮料、浆料，产品中无需添加任何香精香料、色素、酸味剂、稳定剂、防腐剂这些食品添加剂，所有风味由益生菌发酵果蔬原料产生。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978431.3A CN109401994A (zh) | 2018-08-27 | 2018-08-27 | 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978431.3A CN109401994A (zh) | 2018-08-27 | 2018-08-27 | 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109401994A true CN109401994A (zh) | 2019-03-01 |
Family
ID=65463587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978431.3A Pending CN109401994A (zh) | 2018-08-27 | 2018-08-27 | 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109401994A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136130A (zh) * | 2018-08-27 | 2019-01-04 | 南昌大学 | 一株鼠李糖乳杆菌ncu2217 |
| CN109259146A (zh) * | 2018-08-27 | 2019-01-25 | 南昌大学 | 一株具有抑制脂肪肝病变功效的鼠李糖乳杆菌及其应用 |
| CN111154682A (zh) * | 2020-01-16 | 2020-05-15 | 深圳市沁帆科技有限公司 | 一种鼠李糖乳杆菌、微生物菌剂及食物制品 |
| CN113088470A (zh) * | 2021-04-14 | 2021-07-09 | 广东医科大学 | 一株鼠李糖乳杆菌L.rB16及其应用 |
| CN115232774A (zh) * | 2022-08-05 | 2022-10-25 | 广东行海生物科技有限公司 | 一种医用细胞CMU-pb-7及其在制备抗氧化药物中的应用 |
| CN116747246A (zh) * | 2023-06-16 | 2023-09-15 | 广东南芯医疗科技有限公司 | 鼠李糖乳杆菌nx-2在制备抗氧化和抗衰老产品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275905A (zh) * | 2013-05-31 | 2013-09-04 | 江南大学 | 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528 |
| CN103898017A (zh) * | 2014-03-28 | 2014-07-02 | 广西皇氏甲天下乳业股份有限公司 | 源于广西巴马长寿村的鼠李糖乳杆菌在辅助降血脂方面的应用 |
| CN108048347A (zh) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
-
2018
- 2018-08-27 CN CN201810978431.3A patent/CN109401994A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275905A (zh) * | 2013-05-31 | 2013-09-04 | 江南大学 | 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528 |
| CN103898017A (zh) * | 2014-03-28 | 2014-07-02 | 广西皇氏甲天下乳业股份有限公司 | 源于广西巴马长寿村的鼠李糖乳杆菌在辅助降血脂方面的应用 |
| CN108048347A (zh) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | 鼠李糖乳杆菌、鼠李糖乳杆菌制剂及其用途 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109136130A (zh) * | 2018-08-27 | 2019-01-04 | 南昌大学 | 一株鼠李糖乳杆菌ncu2217 |
| CN109259146A (zh) * | 2018-08-27 | 2019-01-25 | 南昌大学 | 一株具有抑制脂肪肝病变功效的鼠李糖乳杆菌及其应用 |
| CN111154682A (zh) * | 2020-01-16 | 2020-05-15 | 深圳市沁帆科技有限公司 | 一种鼠李糖乳杆菌、微生物菌剂及食物制品 |
| CN113088470A (zh) * | 2021-04-14 | 2021-07-09 | 广东医科大学 | 一株鼠李糖乳杆菌L.rB16及其应用 |
| CN115232774A (zh) * | 2022-08-05 | 2022-10-25 | 广东行海生物科技有限公司 | 一种医用细胞CMU-pb-7及其在制备抗氧化药物中的应用 |
| CN115232774B (zh) * | 2022-08-05 | 2023-04-28 | 广东行海生物科技有限公司 | 一种医用细胞CMU-pb-7及其在制备抗氧化药物中的应用 |
| CN116747246A (zh) * | 2023-06-16 | 2023-09-15 | 广东南芯医疗科技有限公司 | 鼠李糖乳杆菌nx-2在制备抗氧化和抗衰老产品中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109401994A (zh) | 一株具有抑制高血脂症功效的鼠李糖乳杆菌及其应用 | |
| CN109136131A (zh) | 一株具有缓解结肠炎功效的鼠李糖乳杆菌及其应用 | |
| CN103598594B (zh) | 植物乳杆菌在降血脂和辅助减肥方面的应用 | |
| CN109259146A (zh) | 一株具有抑制脂肪肝病变功效的鼠李糖乳杆菌及其应用 | |
| CN113498433B (zh) | 包含嗜柠檬酸明串珠菌WiKim0104的用于预防、改善或治疗肥胖或脂肪肝疾病的组合物 | |
| CN109182166A (zh) | 一株具有缓解便秘功效的鼠李糖乳杆菌及其应用 | |
| CN102292431A (zh) | 一种新型植物乳杆菌及含该植物乳杆菌的组合物 | |
| KR20190055552A (ko) | 피부 미백 및 보습개선 활성을 갖는 락토바실러스 플란타럼 WiKim0060 및 이를 포함하는 조성물 | |
| KR20120100608A (ko) | 면역관련 및 염증성 질환의 예방 및 치료 활성을 갖는 신규한 락토바실러스 사케이(Ｌａｃｔｏｂａｃｉｌｌｕｓ ｓａｋｅｉ) Ｋ101 | |
| US10335441B2 (en) | Oral composition containing bifidobacteria and cruciferous vegetable | |
| CN106359904A (zh) | 罗伊氏乳杆菌在替代饲用抗生素中的应用 | |
| KR101838281B1 (ko) | 알레르기성 질환의 개선 활성을 갖는 락토바실러스 커베터스 wikim53 및 이를 포함하는 조성물 | |
| KR101731992B1 (ko) | 면역 활성 및 안정성이 향상된 유산균을 배양하는 방법 | |
| JP2022522727A (ja) | ワイセラ・ヘレニカｗｉｋｉｍ０１０３を含む肥満または脂肪肝疾患の予防、改善または治療用組成物 | |
| CN105613707A (zh) | 枯草芽孢杆菌生物保鲜剂及在大黄鱼保鲜中的应用 | |
| CN112931865A (zh) | 一种富含γ-氨基丁酸的食用氨基酸酵素及其制备方法 | |
| KR101834383B1 (ko) | 항비만 활성을 갖는 와이셀라 시바리아 WIKIM28(Weissella cibaria WIKIM28) 및 이를 포함하는 조성물 | |
| CN101999556B (zh) | 肉牛专用型动物营养素及其制备方法 | |
| KR101992331B1 (ko) | 피부 미백 및 보습개선 활성을 갖는 류코노스톡 시트리움 WiKim0059 및 이를 포함하는 조성물 | |
| CN109864233A (zh) | 一种富含活性植物乳杆菌的发酵苹果汁及其制备方法 | |
| KR100630337B1 (ko) | 손바닥 선인장 열매 발효분말 및 발효유의 제조방법 | |
| KR101838280B1 (ko) | 관절염의 개선 활성을 갖는 류코노스톡 시트리움 wikim56 및 이를 포함하는 조성물 | |
| KR101909927B1 (ko) | 케피어 유래 효모를 포함하는 프로바이오틱스 | |
| CN102669485B (zh) | 肉鸡专用型动物生命素及其制备方法 | |
| KR101828494B1 (ko) | 유산균을 이용한 발효음료의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190301 |
|
| RJ01 | Rejection of invention patent application after publication |